The Endovascular Simulator industry trends have accelerated since early 2023, driven by a surge in cath-lab outsourcing and value-based reimbursement. In March 2024, Siemens Healthineers and Mentice deepened their 2022 alliance with an exclusive co-development pact for a cloud-connected, AI-guided neuro-suite simulator expected to launch in late 2025; the deal bundles Mentice’s VIST software into Siemens’ Artis icono angio systems, giving hospitals a pay-per-use training model that cuts onboarding cost by 40%. Three months later, 3-Dmed was quietly acquired by Surgical Science Sweden AB, adding 1,200 installed units and a U.S. veteran-accounts sales channel that boosts Surgical Science’s North American footprint by 30%. Product launches this year are centered on physiological twins: Biobot Surgical introduced a pulsatile silicone aorta for its EndoVR platform, while CathWorks received FDA 510(k) clearance for an integrated FFR training module in May 2024. Meanwhile, CMS’ 2024 outpatient rule ties 5% bonus payments to procedure-volume maintenance, pushing mid-tier hospitals to lease high-fidelity simulators rather than purchase, a shift forecast to raise recurring revenue share from 28% to 42% by 2026. Venture funding remains robust—FundamentalVR closed a $20 million Series B in Q1 2024, earmarked for expanding haptic gloves into peripheral vascular modules.
